rs2200733 — PITX2 PITX2 4q25 AF susceptibility variant

Intergenic variant at chromosome 4q25 near PITX2 — the strongest GWAS signal for atrial fibrillation susceptibility; the T allele reduces PITX2 expression in the left atrium, impairing suppression of a pacemaker program that normally prevents the left atrium from generating ectopic impulses

See your personal result for PITX2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PITX2 4q25 — The Master Switch for the Left Atrium's Electrical Identity

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 37 million people worldwide and carrying a fivefold increased risk of ischaemic stroke. The variant rs2200733 at chromosome 4q25 is the strongest single GWAS signal ever found for AF susceptibility — discovered in the landmark 2007 Nature paper by Gudbjartsson et al. and since replicated across dozens of populations and hundreds of thousands of participants. The variant sits in a non-coding intergenic region near PITX2 (paired-like homeodomain transcription factor 2)11 PITX2 (paired-like homeodomain transcription factor 2)
a transcription factor essential for left-right body asymmetry and left atrial identity during cardiac development, and its effect is not to alter the PITX2 protein but to reduce how much PITX2 the left atrium produces.

The Mechanism

PITX2 is selectively expressed in the adult left atrium22 left atrium
the upper left chamber of the heart, the primary driver of AF when ectopic electrical impulses originate from pulmonary vein sleeves or the posterior left atrial wall and is largely absent from the right atrium and ventricles. Its role is to maintain the left atrium's distinct "working myocardium" identity by suppressing the sinoatrial node (SAN) pacemaker program33 sinoatrial node (SAN) pacemaker program
the SAN is the heart's natural pacemaker, located in the right atrium; its gene expression profile — rapid automaticity, slow conduction — is appropriate there but catastrophic if it activates in left atrial tissue.

Wang et al. 2010 (PNAS)44 Wang et al. 2010 (PNAS)
Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci USA. 2010;107(21):9753–9758. demonstrated that PITX2 directly binds and represses Shox2 — a master activator of the SAN gene program — along with downstream pacemaker genes HCN4 (funny current channel), Kcnq1 (potassium channel), and Tbx3 (transcription factor). When PITX2 levels fall by even 50% (haploinsufficiency), mice develop atrial flutter and tachycardia upon electrical stimulation, and SAN-specific gene expression inappropriately reactivates in left atrial tissue.

The rs2200733 T allele acts as a regulatory variant that reduces PITX2 expression in the left atrium. The consequence — less PITX2 → less SAN suppression → ectopic automaticity and triggered activity in the pulmonary vein sleeves and posterior left atrial wall → AF. Beyond pacemaker de-suppression, Syeda et al. 201755 Syeda et al. 2017
PITX2-dependent gene regulation in atrial fibrillation and rhythm control. J Physiol. 2017;595(12):4019–4026. established that PITX2 deficiency also drives electrical remodelling (shortened atrial action potential, reduced gap junction coupling) and structural remodelling (fibrosis), both of which sustain AF once initiated. More recently, PITX2 deficiency has been shown to cause atrial mitochondrial dysfunction and a metabolic shift toward glycolysis that may underlie the structural changes.

The Evidence

The original discovery came from Gudbjartsson et al. in a 2007 genome-wide association study66 a 2007 genome-wide association study
Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448(7151):353–357. spanning European and Chinese cohorts. Two variants at 4q25 were identified; rs2200733 was the stronger signal, conferring a 1.72-fold increased risk per copy in Europeans and a 1.42-fold risk per copy in Chinese populations. Approximately 35% of Europeans carry at least one T allele; in East Asian populations the T allele reaches ~49% frequency, making rs2200733 one of the most ethnically variable major AF risk variants.

A 2014 meta-analysis by Ferrán et al.77 Ferrán et al.
Association between rs2200733 and rs7193343 genetic variants and atrial fibrillation in a Spanish population, and meta-analysis of previous studies. Rev Esp Cardiol. 2014;68(5):381–388. pooled data across multiple populations and confirmed an overall OR of 1.71 (95% CI 1.54–1.90) for rs2200733 and AF. This places rs2200733 among the highest-effect common variants in cardiovascular disease genetics — comparable in magnitude to APOE4 for Alzheimer's disease risk.

Population-specific replication in a Greek cohort of 295 individuals Kalinderi et al. 201588 Kalinderi et al. 2015
Hellenic J Cardiol. 2015;56(3):229–235. found the TT genotype in 13.2% of AF patients versus only 2.3% of controls. In Chinese Han subjects Han et al. 202399 Han et al. 2023
Anatol J Cardiol. 2023;27(3):160–166., the TT genotype conferred OR 5.08 (95% CI 1.65–15.6), consistent with East Asian populations' higher T allele frequency and correspondingly higher TT homozygote prevalence.

Beyond risk, rs2200733 predicts treatment response: a 2015 meta-analysis of 991 patients undergoing catheter ablation Shoemaker et al. 20151010 Shoemaker et al. 2015
Circ Arrhythm Electrophysiol. 2015;8(2):296–302. found that rs2200733 T allele carriers had a 1.4-fold increased risk of AF recurrence after ablation (HR 1.3, 95% CI 1.1–1.6), making genotyping clinically relevant for procedure planning.

Practical Actions

For T allele carriers, the priorities are: knowing your genotype's implications for stroke risk so you can act if AF is ever diagnosed; heart rate monitoring to catch paroxysmal AF early; avoiding triggers known to increase AF risk in genetically susceptible individuals; and informing clinical decisions about rhythm vs rate control strategy and ablation prognosis if AF is diagnosed.

The rs2200733 variant does not directly cause AF — it increases susceptibility. Whether AF develops depends on modifying factors including cardiovascular fitness, blood pressure, thyroid function, sleep apnoea, alcohol intake, and body weight. These factors interact with the underlying PITX2 deficiency to determine whether arrhythmia manifests.

Interactions

The 4q25 locus contains multiple AF-associated variants in linkage disequilibrium. rs10033464 is the second significant variant identified by Gudbjartsson et al. (OR ~1.39 per copy in Europeans), located ~10 kb from rs2200733. These variants are partially correlated but represent related yet independent signals at the same PITX2 regulatory locus. Carrying risk alleles at both rs2200733 and rs10033464 compounds AF risk — this combination is a candidate for a compound action.

Several additional 4q25 variants (rs6817105, rs3853445) have been identified in GWAS follow-up studies and may tag additional PITX2 regulatory elements. No pharmacogenomic drug-gene interactions have been formally established, but the Shoemaker 2015 data support using rs2200733 status when counselling patients about ablation prognosis.

Genotype Interpretations

What each possible genotype means for this variant.

CC Low Genetic AF Risk Normal

Common protective genotype; normal PITX2 expression and left atrial electrical identity

You carry two copies of the common C allele at rs2200733. About 65% of people globally share this CC genotype (approximately 76% of Europeans). Your left atrial PITX2 expression is not reduced by this variant, meaning the transcription factor that suppresses ectopic pacemaker activity in the left atrium functions at its full genetically determined level. This does not eliminate AF risk — AF is a complex disease influenced by age, blood pressure, body weight, alcohol intake, sleep apnoea, and other genetic variants — but this particular locus does not add to your risk.

CT Elevated AF Risk Intermediate

One copy of the AF risk allele; moderately reduced PITX2 expression with ~1.7-fold increased AF susceptibility

The CT genotype produces an intermediate reduction in left atrial PITX2 output. With one normal C allele and one risk T allele, some regulatory activity is preserved, but not at wild-type levels. The PITX2 haploinsufficiency model in mice — where removing one Pitx2 copy (equivalent to heterozygosity) produced arrhythmias on electrical stimulation (Wang et al. 2010) — suggests even a 50% reduction in PITX2 is sufficient to impair left atrial pacemaker suppression.

The primary clinical implications for CT carriers are: (1) a genuinely elevated lifetime AF risk that warrants proactive surveillance, particularly as other AF risk factors accumulate with age; and (2) knowledge that if AF is ever diagnosed and ablation is considered, the T allele is associated with higher post-ablation recurrence.

TT High Genetic AF Risk High Risk

Both alleles carry the AF risk variant; substantially elevated AF susceptibility with significant stroke implications

The TT genotype represents the most substantial PITX2 regulatory impairment conferred by this locus. In mouse models, complete Pitx2 removal results in severe structural cardiac defects; in humans, the TT genotype represents a quantitative reduction in PITX2 expression, not complete absence. Nevertheless, the dose-response implied by OR ~1.71 per allele means TT homozygotes have approximately 1.71² ≈ 2.9-fold elevated AF risk per allele-count model — though the Chinese Han study reports OR 5.08, which may reflect non-additive (recessive) effects or population-specific modifier alleles.

The stroke imperative is critical. Undetected paroxysmal AF is a leading cause of embolic stroke, particularly in younger patients without obvious cardiovascular risk factors. The TT genotype markedly elevates the probability that any palpitation episode or unexplained stroke is AF-related. For TT carriers who develop confirmed AF, the CHA₂DS₂-VASc score guides anticoagulation decisions — but even a score of 1 may warrant anticoagulation given the underlying genetic substrate.

In the ablation context, TT carriers would be expected to have the highest recurrence rate of the three genotypes, based on the dose-response pattern observed across CT and TT groups in the Shoemaker 2015 meta-analysis. This has clinical implications for discussing realistic expectations before ablation.